Glaukos Corporation (GKOS)
News
Glaukos Corporation: Ripe For Some Consolidation
SeekingAlpha Glaukos Corporation: Ripe For Some Consolidation...\n more…
Glaukos Stocks Rides on Strong Product Demand Amid Competition
Benzinga Glaukos Corporation (NYSE: GKOS) is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well.\n more…
Rhumbline Advisers Boosts Holdings in Glaukos Co. (NYSE:GKOS)
Ticker Report Rhumbline Advisers lifted its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange...\n more…
Here's Why Glaukos (GKOS) Appreciated in Q2
Insider Monkey Brown Capital Management, an investment management company, released its The Brown Capital Management Small Company Fund second quarter 2024 investor letter. A copy of the letter can be downloaded...\n more…
Natixis Advisors LLC Buys 4,158 Shares of Glaukos Co. (NYSE:GKOS)
Ticker Report Natixis Advisors LLC boosted its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 12.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional...\n more…
Glaukos (NYSE:GKOS) PT Raised to $145.00 at Stifel Nicolaus
Ticker Report Glaukos (NYSE:GKOS - Get Free Report) had its price objective upped by analysts at Stifel Nicolaus from $130.00 to $145.00 in a report released on Tuesday, Benzinga reports. The firm currently has a...\n more…